Efficacy, safety and tolerability of raclopride, a specific D2 receptor blocker, in acute schizophrenia: an open trial.

@article{Cookson1989EfficacySA,
  title={Efficacy, safety and tolerability of raclopride, a specific D2 receptor blocker, in acute schizophrenia: an open trial.},
  author={John C Cookson and B Natorf and Noel Hunt and Trevor Silverstone and Gunilla Uppfeldt},
  journal={International clinical psychopharmacology},
  year={1989},
  volume={4 1},
  pages={61-70}
}
Fifteen acutely ill patients (8 male, 7 female) aged 19 to 63 who met DSM-III criteria for schizophrenic disorder or schizophreniform disorder participated in a 4-week open trial of raclopride. The starting dose of raclopride was 2 mg increasing to 4 mg twice daily in the first week, further increments to 6 mg twice daily at day 14, and 8 mg twice daily at day 21 depending on response. Weekly assessments were made using the BPRS, Montgomery Schizophrenia Scale, Krawiecka-Goldberg Scale and… CONTINUE READING